Tesi Raymond Joseph's Form 4 filing
Inmune Bio, Inc. (INMB) · filed Apr 23, 2024
- Accession no.
- 0001213900-24-035474
- Filed
- Apr 23, 2024, 5:55 PM ET
- Trade date
- Apr 19, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0001213900-24-035722 (Apr 24, 2024). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tesi Raymond JosephCIK 0001767280 | Director, Officer (President and CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 19, 2024 | Common Stock | AGrant or awardAcquired | +18,028 | $8.32 | +$149,992.96 | 1,538,726 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 19, 2024 | Common Stock | AGrant or awardAcquired | +18,028 | $0.125 | +$2,253.5 | 18,028 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.